Skip to Content

A Quality, Undervalued Healthcare Firm

A Quality, Undervalued Healthcare Firm

Vishnu Lekraj: Today we are talking about McKesson Corp, a large global drug distributor.

What McKesson does is source drugs around the globe from different manufacturers, both generics and branded, and brings them into the U.S. and ships them to retail outlets--both large chains like Walgreens and smaller retail pharmacy firms. McKesson's unparalleled volume, its wide economic moat, and deep entrenchment within the pharmaceutical supply chain has created an environment for it to produce ROICs well above its weighted average cost of capital. We believe this trend will last over the longer term.

Many of the near-term issues McKesson has faced, in terms of drug pricing downturns, issues with client contract losses, are in the short term and will abate. Recent results for McKesson have pointed into this direction.

We believe the firm's undervalued stock, wide economic moat, and quality operations give investors an opportunity here to own a very quality firm at undervalued price.

More in Personal Finance

About the Author

Vishnu Lekraj

Senior Equity Analyst
More from Author

Vishnu Lekraj is a senior equity analyst for Morningstar Research Services LLC, a wholly owned subsidiary of Morningstar, Inc. He covers the healthcare services industry.

Lekraj joined Morningstar in 2008 after receiving a master’s degree in business administration from the University of Florida’s Hough Graduate School of Business. Before business school, he was a financial analyst for HSBC bank.

Lekraj holds a bachelor’s degree in finance from the Warrington College of Business Administration at the University of Florida, where he graduated summa cum laude. He is also a member of the Beta Gamma Sigma international honor society. In 2012, Lekraj ranked first in the professional services industry in the StarMine Analyst Awards, presented by the Financial Times.

Sponsor Center